
Sign up to save your podcasts
Or


Ambassador Alon Pinkas, former Israel General Consel in New York, former Chief of Staff to two foreign minister, and former advisor on US affairs to former Israeli Prime Minister Ehud Barak, joins to discuss the latest on the Israel-Hamas war. Bloomberg’s Alix Steel and Guy Johnson interview Chevron CEO Mike Wirth and Hess CEO John Hess on their merger. RJ Gallo, Senior Portfolio Manager, Fixed Income at Federated Hermes, joins to discuss the bond rout and outlook for the bond market. Elizabeth Hurd, Chair of Religious Studies and Professor of Political Science at Northwestern, joins to contextualize the history and geopolitics of the Israel-Hamas war. Fraser Atkinson, CEO of Greenpower Motor Company (NASDAQ: GP), joins to discuss his company’s aim to make battery-electric buses and trucks affordable and other green power initiatives. Joel Lewis, CEO at Galectin Therapeutics (NASDAQ: GALT), joins to discuss his firm, medical trials, and the market potential for their current drug development. Hosted by Paul Sweeney and Matt Miller.
See omnystudio.com/listener for privacy information.
By Bloomberg3.8
381381 ratings
Ambassador Alon Pinkas, former Israel General Consel in New York, former Chief of Staff to two foreign minister, and former advisor on US affairs to former Israeli Prime Minister Ehud Barak, joins to discuss the latest on the Israel-Hamas war. Bloomberg’s Alix Steel and Guy Johnson interview Chevron CEO Mike Wirth and Hess CEO John Hess on their merger. RJ Gallo, Senior Portfolio Manager, Fixed Income at Federated Hermes, joins to discuss the bond rout and outlook for the bond market. Elizabeth Hurd, Chair of Religious Studies and Professor of Political Science at Northwestern, joins to contextualize the history and geopolitics of the Israel-Hamas war. Fraser Atkinson, CEO of Greenpower Motor Company (NASDAQ: GP), joins to discuss his company’s aim to make battery-electric buses and trucks affordable and other green power initiatives. Joel Lewis, CEO at Galectin Therapeutics (NASDAQ: GALT), joins to discuss his firm, medical trials, and the market potential for their current drug development. Hosted by Paul Sweeney and Matt Miller.
See omnystudio.com/listener for privacy information.

972 Listeners

1,171 Listeners

2,183 Listeners

438 Listeners

971 Listeners

194 Listeners

1,045 Listeners

189 Listeners

70 Listeners

1,313 Listeners

68 Listeners

76 Listeners

30 Listeners

65 Listeners

4 Listeners

58 Listeners

233 Listeners

229 Listeners

65 Listeners

89 Listeners

85 Listeners

79 Listeners

84 Listeners

396 Listeners

21 Listeners

12 Listeners

8 Listeners

2 Listeners

120 Listeners

23 Listeners